All endocrine glands are susceptible to neoplastic growth, yet the health consequences of
these neoplasms differ between endocrine tissues. Pituitary neoplasms are highly prevalent …

In the 2022 fifth edition of the WHO Classification of Endocrine Tumours and of Central
Nervous System Tumours, pituitary adenomas are reclassified as neuroendocrine tumours …

The latest edition of the WHO classification of the central nervous system was published in
2021. This review summarizes the major revisions to the classification of anterior pituitary …

Growth hormone (GH)-secreting pituitary tumours represent the most genetically determined
pituitary tumour type. This is true both for germline and somatic mutations. Germline …

Purpose Surgical workflow analysis seeks to systematically break down operations into
hierarchal components. It facilitates education, training, and understanding of surgical …

Pituitary tumors (PT) represent in, the majority of cases, benign tumors for which surgical
treatment still remains, except for prolactin-secreting PT, the first-line therapeutic option …

ABSTRACT Pituitary adenomas comprise approximately 10-20% of intracranial tumors. Non-
functioning pituitary adenomas (NFPAs) are benign adenohypophyseal tumors not …

The majority of anterior pituitary tumors behave benignly, that is, they grow slowly and do not
metastasize, and were therefore called adenomas. However, they would frequently invade …

Disease classification, fundamental to accurately reflecting critical knowledge of disease
causes and consequences, underpins clinical care, service planning, payments, safety, and …

No comprehensive classification system that guides prognosis and therapy of pituitary
adenomas exists. The 2022 WHO histopathology-based classification system can only be …